An app and guidelines were launched to treat chronic disease diabetes.
The application will work based on the “Diabetes Care BADAS Guideline”. The diabetes treatment guideline was prepared jointly by the Diabetic Association of Bangladesh (BADAS) and Non-Communicable Diseases (NCD) Control Programme of Directorate General of Health Services (DGHS).
The dissemination programme of application and guideline started at a hotel in the capital on Friday.
BADAS has introduced application and prepared guideline with the support of Novo Nordisk. A countrywide training programme will be rolled out for the physicians on how to use this application.
The application and guideline are developed as a supporting tool for physicians and empower them to select the right medication for the patients living with diabetes, said Professor Dr AK Azad Khan, president of BADAS.
The number of diabetic people is increasing at an alarming rate and that’s why quality treatment is essential for these patients, said Professor Akhtar Hussain, president (elect), International Diabetes Federation.
The application and guideline will ensure quality treatment and help patients to live a complication-free life, he said.
Improving treatment capacity of the doctors is also a demand of the time and these initiatives are aligned with the modernising treatment of diabetes management, said Professor Md Robed Amin, Line Director, NCD Control Program of DGHS.
BADAS with the support of Novo Nordisk has taken many initiatives to introduce digital approach in healthcare, said Md Sayef Uddin, secretary general of BADAS.
The diabetes journey application and the country’s first nationwide diabetes patients’ registry are few examples of digitalisation in Bangladesh and are aligned with the government’s vision for “Digital Bangladesh,” he said, according to a statement.
Dr Abu Hussain Md Moinul Ahsan, civil surgeon of Dhaka; Professor Md. Faruque Pathan, president of Bangladesh Endocrine Society; Dr M A Samad, chief executive officer of National Healthcare Network; Professor M K I Quayyum Choudhury, director-general, BIRDEM General Hospital; Dr. Bishwajit Bhowmik, general secretary of Diabetes Asia Study Group and Coordinator, Centre for Global health Research; Dr. Abdul Alim, programme manager, NCD Control Program of DGHS; Mr. Tanbir Sajib, director of commercial affairs of Novo Nordisk; and Dr. Mohammad Mahbubur Rahman, director of clinical, medical, regulatory and quality affairs of Novo Nordisk were present in the programme.
